NCT07189455View on ClinicalTrials.gov

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

December 31, 2028

Conditions
Small-cell Lung Cancer
Interventions
DRUG

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

DRUG

Topotecan

Topotecan will be administered per local standard of care

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY